Effect of Early Administration of TXA in Adult Hip Fractures

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ascension Genesys Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• 1. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

Exclusion Criteria:

1. Polytrauma patients

2. Previous operation on the ipsilateral hip

3. Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)

4. Patients with < 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)

5. History of seizure disorder

6. Patients on birth control

7. Pregnant Women

8. Prisoners

9. Active thromboembolic disease (DVT/PE, MI, Stroke)